This discussion focused on tools that may be useful in analyzing the likelihood of clinical and regulatory success and the value of health care and life sciences treatments in development. Panelists offered academic and industry perspectives on economic issues in this area, including clinical success rates, deal valuation, and methodological considerations in calculating the value of emerging biotechnology.

Panelists

Amitabh Chandra

Henry and Allison McCance Professor of Business Administration, Harvard Business School; Ethel Zimmerman Wiener Professor of Public Policy and Director of Health Policy Research, Harvard Kennedy School